Biofactura Inc
CAGE Code: 339S7
NCAGE Code: 339S7
Status: Active
Type: Manufacturer
Dun & Bradstreet (DUNS): 168920143
Summary
Biofactura Inc is an Active Manufacturer with the Cage Code 339S7 and is tracked by Dun & Bradstreet under DUNS Number 168920143..
Address
8435 Progress Dr
Ste Y-Z
Frederick MD 21701-4979
United States
Points of Contact
Related Information
People who viewed this 'CAGE Code' also viewed...
Visionware Corp National Target Company, Inc Reeves Mfg Inc M C Controls Corp Sac-Tec Micro Devices Inc Engineering Systems Solutions Inc. International Software Services Inc Standard Electromagnetics Inc Micronel Inc Designs, Furniture & Installation Softrac America Inc Cetrom, Inc Ayikaz Solutions, Llc Risehands Llc Boddicker Electric Supply Inc Universe Technologies Inc Sarjos Unlimited Fort Detrick Community Club Invitrogen Corporation Radiometrics Corporation
Frequently Asked Questions (FAQ) for CAGE 339S7
- What is CAGE Code 339S7?
- 339S7 is the unique identifier used by NATO Organizations to reference the physical entity known as Biofactura Inc located at 8435 Progress Dr, Ste Y-Z, Frederick MD 21701-4979, United States.
- Who is CAGE Code 339S7?
- 339S7 refers to Biofactura Inc located at 8435 Progress Dr, Ste Y-Z, Frederick MD 21701-4979, United States.
- Where is CAGE Code 339S7 Located?
- CAGE Code 339S7 is located in Frederick, MD, USA.
Contracting History for CAGE 339S7 Most Recent 25 Records
- HDTRA120C0033
- Sbir Phase Ii Manufacture Of An Antibody-Based Therapy Against Marburg Virus.
- 9 Jun 2022
- Sbir Phase Ii Manufacture Of An Antibody-Based Therapy Against Marburg Virus.
- Defense Threat Reduction Agency
- Department Of Defense (Dod)
- $999,398.93
- Department Of Defense (Dod)
- 75A50119C00054
- This Contract Includes Preclinical And Manufacturing Development Activities Including Cell Line Development; Process Development; Non-Clinical Efficacy Studies; Non-Clinical Safety Studies; Manufacturing Activities; Clinical Activities; And All As
- 15 Apr 2021
- This Contract Includes Preclinical And Manufacturing Development Activities Including Cell Line Development; Process Development; Non-Clinical Efficacy Studies; Non-Clinical Safety Studies; Manufacturing Activities; Clinical Activities; And All As
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $22,493,986.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00054
- Modification 11 Extends The Pop Of Base Period To End On October 20, 2023 At No Extra Cost To The Government.
- 18 Nov 2022
- Modification 11 Extends The Pop Of Base Period To End On October 20, 2023 At No Extra Cost To The Government.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $39,141,574.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00054
- Revised Option 2 Is Exercised With A New Funding Amount Of $15,899,969.
- 28 Jun 2022
- Revised Option 2 Is Exercised With A New Funding Amount Of $15,899,969.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $39,141,574.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00054
- Eo14042 - The Advancement Of The Development Of A Smallpox Biodefense Therapeutic To The Clinical Stage As An Antibody-Based Countermeasure
- 1 Dec 2021
- Eo14042 - The Advancement Of The Development Of A Smallpox Biodefense Therapeutic To The Clinical Stage As An Antibody-Based Countermeasure
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $22,493,986.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00054
- Add Funding To Option 2 (Clin 0003) In The Amount Of $928,249.32. This Includes $269,855.08 To Account For G&A And Fee As Well As $658,394.25 For Additional Manufacture Of Anti-Id Abs For Methods Development.
- 16 Jun 2023
- Add Funding To Option 2 (Clin 0003) In The Amount Of $928,249.32. This Includes $269,855.08 To Account For G&A And Fee As Well As $658,394.25 For Additional Manufacture Of Anti-Id Abs For Methods Development.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $41,777,041.50
- Department Of Health And Human Services (Hhs)
- 75A50119C00054
- The Advancement Of The Development Of A Smallpox Biodefense Therapeutic To The Clinical Stage As An Antibody-Based Countermeasure
- 24 Feb 2022
- The Advancement Of The Development Of A Smallpox Biodefense Therapeutic To The Clinical Stage As An Antibody-Based Countermeasure
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $22,493,986.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00054
- The Advancement Of The Development Of A Smallpox Biodefense Therapeutic To The Clinical Stage As An Antibody-Based Countermeasure
- 4 Mar 2022
- The Advancement Of The Development Of A Smallpox Biodefense Therapeutic To The Clinical Stage As An Antibody-Based Countermeasure
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $22,493,986.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00054
- Modification 12 Adds Funding In The Amount Of $1,707,218.18 To Clin 0003 Option Period 2
- 7 Mar 2023
- Modification 12 Adds Funding In The Amount Of $1,707,218.18 To Clin 0003 Option Period 2
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $40,848,792.18
- Department Of Health And Human Services (Hhs)
- 75A50119C00054
- The Purpose Of This Bilateral Modification Is To 1. Extend The Period Of Performance For The Base Period At No Cost To The Government. As A Result Of This Modification The Period Of Performance Is Hereby Changed From September 25,2019 Through Oct
- 18 Oct 2023
- The Purpose Of This Bilateral Modification Is To 1. Extend The Period Of Performance For The Base Period At No Cost To The Government. As A Result Of This Modification The Period Of Performance Is Hereby Changed From September 25,2019 Through Oct
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $58,020,389.50
- Department Of Health And Human Services (Hhs)
- 75A50119C00054
- New Contracting Officer For This Contract Is Jonathan Gonzalez
- 3 Jun 2022
- New Contracting Officer For This Contract Is Jonathan Gonzalez
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $23,241,605.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00054
- The Purposes Of This Modification Are To 1. Add Funding To Option 2 (Clin 0003) In The Amount Of $230,896.03. 2. Exercise Option 4 (Clin 0005) In The Amount Of $16,012,452.00. 3. Change The Cor From Malen Link To Carol Diaz-Diaz
- 20 Sep 2023
- The Purposes Of This Modification Are To 1. Add Funding To Option 2 (Clin 0003) In The Amount Of $230,896.03. 2. Exercise Option 4 (Clin 0005) In The Amount Of $16,012,452.00. 3. Change The Cor From Malen Link To Carol Diaz-Diaz
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $58,020,389.50
- Department Of Health And Human Services (Hhs)
- 75A50119C00054
- The Advancement Of The Development Of A Smallpox Biodefense Therapeutic To The Clinical Stage As An Antibody-Based Countermeasure
- 23 May 2022
- The Advancement Of The Development Of A Smallpox Biodefense Therapeutic To The Clinical Stage As An Antibody-Based Countermeasure
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $23,241,605.00
- Department Of Health And Human Services (Hhs)